Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
1.990
+0.010 (0.51%)
May 14, 2025, 11:30 AM CST
Kangmei Pharmaceutical Revenue
Kangmei Pharmaceutical had revenue of 1.30B CNY in the quarter ending March 31, 2025, with 8.16% growth. This brings the company's revenue in the last twelve months to 5.29B, up 7.22% year-over-year. In the year 2024, Kangmei Pharmaceutical had annual revenue of 5.19B with 6.47% growth.
Revenue (ttm)
5.29B
Revenue Growth
+7.22%
P/S Ratio
5.19
Revenue / Employee
1.20M
Employees
4,409
Market Cap
27.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.19B | 315.12M | 6.47% |
Dec 31, 2023 | 4.87B | 693.87M | 16.60% |
Dec 31, 2022 | 4.18B | 27.63M | 0.67% |
Dec 31, 2021 | 4.15B | -1.26B | -23.27% |
Dec 31, 2020 | 5.41B | -6.03B | -52.72% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Sichuan Biokin Pharmaceutical | 5.82B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |